Extended Duration Parenteral Products as Patient Adherence Strategies
For a number of years, extended-release parenteral formulations have garnered enormous attention due to their effective drug concentrations over extended periods and improve patient compliance through reduced administration frequency. As a result, many drug delivery systems including nano suspensions, lipid micro/nanopartoiculate systems, implants and more have been explored resulting in numerous products approved on the market. However, adherence remains one if the biggest challenges for drug manufacturers. Are you up-to-speed on the benefits of developing advanced extended-release formulations, and how these could benefit patients?
This week’s available download is titled “Extended Duration Parenteral Products as Patient Adherence Strategies” from Marian Gindy at Merck & Co. This presentation discusses patient adherence in disease management and the problem of non-adherence as well as factors affecting medication adherence. It also examines extended duration parenteral formulations and a series of examples including extended duration dosing in HIV prevention and treatment amongst others.
Our goal is to help you improve the performance of your drug products. Would you like to learn new strategies to improve patient compliance, bioavailability, stability and efficacy, all while reducing dosage, cost and decreasing time-to-market?
Don’t miss your opportunity to join industry’s leading drug development innovators and experts at the 2021 Controlled & Modified Drug Release (CR7) & 2021 Peptide Drug Design & Delivery (PEP5) Summits, and walk away with 2 years worth of new product development strategies in just 3 days!
This industry-leading event will bring together key decision makers and innovators within this rapidly growing space. By attending this unique event, you will learn directly from industry’s leading experts and hear unique case study sessions and take-home examples to enhance your product pipeline. Gather insights into the latest technologies and methods in improving drug release mechanisms, maximizing exposure, and reducing time-to-market. Additionally, this must-attend event will showcase the latest regulatory guidance updates and the implications for the industry.
Why consider attending the CR7 & PEP5 Summits?
- 60+ leading industry-led speaker faculty over 3 full days sharing innovative drug development take-home strategies
- 14+ hours of networking and breakout sessions, including evening cocktail reception
- 160+ senior participants senior participants spanning pharma, biotech and specialty delivery and formulation providers
- 2 Events for the Price of 1! Attendees gain access to both events and all networking receptions / tech showcase exhibits for one registration. Group discounts available also!
- Dynamic exhibit hall with multiple leading formulation and drug delivery technology experts
Join over 1250 senior drug product development professionals in our free Novel Drug Discovery & Development Group. Members of this rapidly growing group will benefit by gaining access to an exclusive network of industry and academic professionals within the drug development arena. Members specialize in discovery, development, formulation, delivery and commercialization of innovative drug products.
Want to hear multiple weekly drug product development strategies and approaches from leading organizations and experts? Subscribe here and receive new podcast episodes, presentations, white papers, tips and resources directly from Curtis & Coulter weekly to your inbox